VisEn Medical Establishes Program To Develop and Apply Fluorescence In Vivo Imaging Technologies In Pharmaceutical R&D

VisEn Medical, Inc.

VisEn Medical Establishes Program To Develop and Apply Fluorescence In Vivo Imaging Technologies In Pharmaceutical R&D

November 29, 2006

Woburn, MA November 29, 2006 VisEn Medical, Inc. today announced that it has entered into a joint research program to expand the capabilities and accelerate the adoption of VisEn's in vivo fluorescence technologies in Eli Lilly and Companys research and development programs. Lilly has been working with VisEn's portfolio of in vivo fluorescence probes and Fluorescence Molecular Tomography (FMT) imaging systems as part of their new molecular imaging center and preclinical development programs. This research program is intended to further the development and expand the application of VisEn's leading fluorescence in vivo imaging technologies in pharmaceutical drug development.

Kirtland G. Poss, President and Chief Executive Officer of VisEn added, "Lilly is clearly a recognized leader in developing innovative medicines and applying novel technologies to accelerate and enhance research and drug development. This expanded research program represents an important step in VisEn's mission of working closely with leaders in the field to develop and translate the highest performance fluorescence imaging technologies from research into clinical medicine.

VisEn's fluorescence imaging technologies and products provide the industrys most robust and accurate imaging performance in identifying, characterizing and quantifying a range of biological processes in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research and more efficient drug development. Importantly, VisEn's technologies are also designed for biocompatibility and translation from pre-clinical imaging to clinical imaging in the future.

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing todays highest performing fluorescence molecular imaging technology platforms, from research through medicine. VisEn also works directly with its partners to design ranges of tailored probes and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group. For further information please visit www.visenmedical.com

About VisEn's Technologies and Products

Fluorescence Molecular Tomography (FMT) System: Provides rapid and absolute quantification and true 3D tomography of fluorescence in mouse models of disease.

Near Infrared (NIR) Fluorescence Probe Portfolio: The leading series of in vivo imaging probes tailored to enable a range of imaging readouts on key disease-associated biological processes, including angiogenesis, protease activity, vascular permeability, inflammation, cell migration and tracking, and bone remodeling.

Contact:

Kirtland G. Poss (corporate)
President and CEO
VisEn Medical, Inc.
781-932-6875 X 301

Bryan P. Murphy or Donna LaVoie
LaVoie Group
781.596.0200 X 105/103
bmurphy@lavoiegroup.com or dlavoie@lavoiegroup.com